X-linked inhibitor of apoptosis (XIAP) - a critical death-resistance regulator and therapeutic target for personalized cancer therapy

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Obexer, Petra ^a,b   Ausserlechner, Michael ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AT 406; BCL2 RELATED PROTEIN A1; BIRINAPANT; CASPASE 3; CASPASE 7; CASPASE 9; CISPLATIN; COMPOUND 21; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; HGS 1029; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SM 12D; SMALL INTERFERING RNA; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ANOIKIS; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER THERAPY; CELL DEATH; CELLULAR STRESS SIGNAL; DNA DAMAGE; DNA REPAIR; ENDOCYTOSIS; ESOPHAGUS CARCINOMA; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; METASTASIS; NEOPLASM; NONHODGKIN LYMPHOMA; OLIGOMERIZATION; OVARY CARCINOMA; PERITONEUM CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84904612262     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00197     Document Type: Article

References (87)

1. Akyurek, N., Ren, Y., Rassidakis, G.Z., Schlette, E.J., and Medeiros, L.J. (2006). Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer. 107, 1844-1851.
2. Amantana, A., London, C.A., Iversen, P.L., and Devi, G.R. (2004). X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol.Cancer Ther. 3, 699-707.
3. Ardecky, R.J., Welsh, K., Finlay, D., Lee, P.S., Gonzalez-Lopez, M., Ganji, S.R., Ravanan, P., Mace, P.D., Riedl, S.J., Vuori, K., Reed, J.C., and Cosford, N.D. (2013). Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP. Bioorg.Med.Chem.Lett. 23, 4253-4257.
4. Baykara, M., Yaman, M., Buyukberber, S., Tufan, G., Demirci, U., Benekli, M., Coskun, U., Ozet, A., and Umit, B.E. (2013). Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer. J.BUON. 18, 921-927.
5. Berezovskaya, O., Schimmer, A.D., Glinskii, A.B., Pinilla, C., Hoffman, R.M., Reed, J.C., and Glinsky, G.V. (2005). Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 65, 2378-2386.
6. Bertrand, M.J., Milutinovic, S., Dickson, K.M., Ho, W.C., Boudreault, A., Durkin, J., Gillard, J.W., Jaquith, J.B., Morris, S.J., and Barker, P.A. (2008). cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol.Cell. 30, 689-700.
7. Brunckhorst, M.K., Lerner, D., Wang, S., and Yu, Q. (2012). AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol.Ther. 13, 804-811.
8. Carter, B.Z., Mak, D.H., Morris, S.J., Borthakur, G., Estey, E., Byrd, A.L., Konopleva, M., Kantarjian, H., and Andreeff, M. (2011). XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 16, 67-74.
9. Chawla-Sarkar, M., Bae, S.I., Reu, F.J., Jacobs, B.S., Lindner, D.J., and Borden, E.C. (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death.Differ. 11, 915-923.
10. Choi, Y.E., Butterworth, M., Malladi, S., Duckett, C.S., Cohen, G.M., and Bratton, S.B. (2009). The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J.Biol.Chem. 284, 12772-12782.
11. Condon, S.M., Mitsuuchi, Y., Deng, Y., Laporte, M.G., Rippin, S.R., Haimowitz, T., Alexander, M.D., Kumar, P.T., Hendi, M.S., Lee, Y.H., Benetatos, C.A., Yu, G., Kapoor, G.S., Neiman, E., Seipel, M.E., Burns, J.M., Graham, M.A., McKinlay, M.A., Li, X., Wang, J., Shi, Y., Feltham, R., Bettjeman, B., Cumming, M.H., Vince, J.E., Khan, N., Silke, J., Day, C.L., and Chunduru, S.K. (2014). Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies. J.Med.Chem.
12. Conner, S.H., Kular, G., Peggie, M., Shepherd, S., Schuttelkopf, A.W., Cohen, P., and Van Aalten, D.M. (2006). TAK1-binding protein 1 is a pseudophosphatase. Biochem.J. 399, 427- 434.
13. Coultas, L. and Strasser, A. (2003). The role of the Bcl-2 protein family in cancer. Semin.Cancer Biol. 13, 115-123.
14. Czabotar, P.E., Lessene, G., Strasser, A., and Adams, J.M. (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat.Rev.Mol.Cell Biol. 15, 49-63.
15. Damgaard, R.B., Nachbur, U., Yabal, M., Wong, W.W., Fiil, B.K., Kastirr, M., Rieser, E., Rickard, J.A., Bankovacki, A., Peschel, C., Ruland, J., Bekker-Jensen, S., Mailand, N., Kaufmann, T., Strasser, A., Walczak, H., Silke, J., Jost, P.J., and Gyrd-Hansen, M. (2012).The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol.Cell. 46, 746-758.
16. Dikic, I., Wakatsuki, S., and Walters, K.J. (2009). Ubiquitin-binding domains - from structures to functions. Nat.Rev.Mol.Cell Biol. 10, 659-671.
17. Dynek, J.N., Goncharov, T., Dueber, E.C., Fedorova, A.V., Izrael-Tomasevic, A., Phu, L., Helgason, E., Fairbrother, W.J., Deshayes, K., Kirkpatrick, D.S., and Vucic, D. (2010). c- IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29, 4198-4209.
18. Ea, C.K., Deng, L., Xia, Z.P., Pineda, G., and Chen, Z.J. (2006). Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol.Cell. 22, 245-257.
19. Eckelman, B.P., Salvesen, G.S., and Scott, F.L. (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7, 988-994.
20. Eschenburg, G., Eggert, A., Schramm, A., Lode, H.N., and Hundsdoerfer, P. (2012). Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-alphaindependent apoptosis. Cancer Res. 72, 2645-2656.
21. Fakler, M., Loeder, S., Vogler, M., Schneider, K., Jeremias, I., Debatin, K.M., and Fulda, S. (2009). Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood. 19;113, 1710-1722.
22. Flygare, J.A., Beresini, M., Budha, N., Chan, H., Chan, I.T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S.G., Elliott, L.O., Feng, B., Franklin, M.C., Reisner, S.F., Gazzard, L., Halladay, J., Hymowitz, S.G., La, H., LoRusso, P., Maurer, B., Murray, L., Plise, E., Quan, C., Stephan, J.P., Young, S.G., Tom, J., Tsui, V., Um, J., Varfolomeev, E., Vucic, D., Wagner, A.J., Wallweber, H.J., Wang, L., Ware, J., Wen, Z., Wong, H., Wong, J.M., Wong, M., Wong, S., Yu, R., Zobel, K., and Fairbrother, W.J. (2012). Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J.Med.Chem. 55, 4101-4113.
23. Fulda, S. and Vucic, D. (2012). Targeting IAP proteins for therapeutic intervention in cancer. Nat.Rev.Drug Discov. 11, 109-124.
24. Fulda, S., Wick, W., Weller, M., and Debatin, K.M. (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat.Med. 8, 808-815.
25. Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, A.I., Rickard, J.A., Anderton, H., Wong, W.W., Nachbur, U., Gangoda, L., Warnken, U., Purcell, A.W., Silke, J., and Walczak, H. (2011). Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 471, 591-596.
26. Gillissen, B., Richter, A., Richter, A., Overkamp, T., Essmann, F., Hemmati, P.G., Preissner, R., Belka, C., and Daniel, P.T. (2013). Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bakindependent 'type I' mode. Cell Death.Dis. 4:e643. doi: 10.1038/cddis.2013.67., e643.
27. Gonzalez-Lopez, M., Welsh, K., Finlay, D., Ardecky, R.J., Ganji, S.R., Su, Y., Yuan, H., Teriete, P., Mace, P.D., Riedl, S.J., Vuori, K., Reed, J.C., and Cosford, N.D. (2011). Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP. Bioorg.Med.Chem.Lett. 21, 4332-4336.
28. Gyrd-Hansen, M., Darding, M., Miasari, M., Santoro, M.M., Zender, L., Xue, W., Tenev, T., da Fonseca, P.C., Zvelebil, M., Bujnicki, J.M., Lowe, S., Silke, J., and Meier, P. (2008). IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat.Cell Biol. 10, 1309-1317.
29. Gyrd-Hansen, M. and Meier, P. (2010). IAPs: from caspase inhibitors to modulators of NFkappaB, inflammation and cancer. Nat.Rev.Cancer. 10, 561-574.
30. Han, J., Goldstein, L.A., Gastman, B.R., and Rabinowich, H. (2006). Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis. J.Biol Chem. 281, 10153-10163.
31. Harlin, H., Reffey, S.B., Duckett, C.S., Lindsten, T., and Thompson, C.B. (2001). Characterization of XIAP-deficient mice. Mol.Cell Biol. 21, 3604-3608.
32. Hofmann, H.S., Simm, A., Hammer, A., Silber, R.E., and Bartling, B. (2002). Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J.Cancer Res.Clin.Oncol. 128, 554-560.
33. Hu, Y., Cherton-Horvat, G., Dragowska, V., Baird, S., Korneluk, R.G., Durkin, J.P., Mayer, L.D., and Lacasse, E.C. (2003). Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin.Cancer Res. 9, 2826-2836.
34. Hundsdoerfer, P., Dietrich, I., Schmelz, K., Eckert, C., and Henze, G. (2010). XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr.Blood Cancer. 55, 260-266.
35. Janssens, S., Tinel, A., Lippens, S., and Tschopp, J. (2005). PIDD mediates NF-kappaB activation in response to DNA damage. Cell. 123, 1079-1092.
36. Jost, P.J., Grabow, S., Gray, D., McKenzie, M.D., Nachbur, U., Huang, D.C., Bouillet, P., Thomas, H.E., Borner, C., Silke, J., Strasser, A., and Kaufmann, T. (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 460, 1035-1039.
37. Kester, R.F., Donnell, A.F., Lou, Y., Remiszewski, S.W., Lombardo, L.J., Chen, S., Le, N.T., Lo, J., Moliterni, J.A., Han, X., Hogg, J.H., Liang, W., Michoud, C., Rupert, K.C., Mischke, S., Le, K., Weisel, M., Janson, C.A., Lukacs, C.M., Fretland, A.J., Hong, K., Polonskaia, A., Gao, L., Li, S., Solis, D.S., Aguilar, D., Tardell, C., Dvorozniak, M., Tannu, S., Lee, E.C., Schutt, A.D., and Goggin, B. (2013). Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain. J.Med.Chem. 56, 7788-7803.
38. Lacasse, E.C. (2013). Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett. 332, 215-224.
39. Lee, T.J., Jung, E.M., Lee, J.T., Kim, S., Park, J.W., Choi, K.S., and Kwon, T.K. (2006). Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol.Cancer Ther. 5, 2737-2746.
40. Lima, R.T., Martins, L.M., Guimaraes, J.E., Sambade, C., and Vasconcelos, M.H. (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 11, 309- 316.
41. Loeder, S., Drensek, A., Jeremias, I., Debatin, K.M., and Fulda, S. (2010). Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int.J.Cancer. 126, 2216-2228.
42. Lu, J., Bai, L., Sun, H., Nikolovska-Coleska, Z., McEachern, D., Qiu, S., Miller, R.S., Yi, H., Shangary, S., Sun, Y., Meagher, J.L., Stuckey, J.A., and Wang, S. (2008). SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 68, 9384-9393.
43. Lu, M., Lin, S.C., Huang, Y., Kang, Y.J., Rich, R., Lo, Y.C., Myszka, D., Han, J., and Wu, H. (2007). XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol.Cell. 26, 689-702.
44. Lu, M., Lin, S.C., Huang, Y., Kang, Y.J., Rich, R., Lo, Y.C., Myszka, D., Han, J., and Wu, H. (2007). XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol.Cell. 26, 689-702.
45. Lukacs, C., Belunis, C., Crowther, R., Danho, W., Gao, L., Goggin, B., Janson, C.A., Li, S., Remiszewski, S., Schutt, A., Thakur, M.K., Singh, S.K., Swaminathan, S., Pandey, R., Tyagi, R., Gosu, R., Kamath, A.V., and Kuglstatter, A. (2013). The structure of XIAP BIR2: understanding the selectivity of the BIR domains. Acta Crystallogr.D.Biol.Crystallogr. 69, 1717-1725.
46. Mace, P.D., Smits, C., Vaux, D.L., Silke, J., and Day, C.L. (2010). Asymmetric recruitment of cIAPs by TRAF2. J.Mol.Biol. 400, 8-15.
47. MacFarlane, M., Merrison, W., Bratton, S.B., and Cohen, G.M. (2002). Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro.J.Biol.Chem. 277, 36611-36616.
48. Mansouri, A., Zhang, Q., Ridgway, L.D., Tian, L., and Claret, F.X. (2003). Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol.Res. 13, 399-404.
49. Mizutani, Y., Nakanishi, H., Li, Y.N., Matsubara, H., Yamamoto, K., Sato, N., Shiraishi, T., Nakamura, T., Mikami, K., Okihara, K., Takaha, N., Ukimura, O., Kawauchi, A., Nonomura, N., Bonavida, B., and Miki, T. (2007). Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int.J.Oncol. 30, 919-925.
50. Moldoveanu, T., Follis, A.V., Kriwacki, R.W., and Green, D.R. (2014). Many players in BCL-2 family affairs. Trends Biochem.Sci. 39, 101-111.
51. Moulin, M., Anderton, H., Voss, A.K., Thomas, T., Wong, W.W., Bankovacki, A., Feltham, R., Chau, D., Cook, W.D., Silke, J., and Vaux, D.L. (2012). IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J. 31, 1679-1691.
52. Ndubaku, C., Varfolomeev, E., Wang, L., Zobel, K., Lau, K., Elliott, L.O., Maurer, B., Fedorova, A.V., Dynek, J.N., Koehler, M., Hymowitz, S.G., Tsui, V., Deshayes, K., Fairbrother, W.J., Flygare, J.A., and Vucic, D. (2009). Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem.Biol. 4, 557-566.
53. Nikolovska-Coleska, Z., Xu, L., Hu, Z., Tomita, Y., Li, P., Roller, P.P., Wang, R., Fang, X., Guo, R., Zhang, M., Lippman, M.E., Yang, D., and Wang, S. (2004). Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J.Med.Chem. 47, 2430-2440.
54. Nomura, T., Yamasaki, M., Nomura, Y., and Mimata, H. (2005). Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol.Rep. 14, 993-997.
55. Oberoi, T.K., Dogan, T., Hocking, J.C., Scholz, R.P., Mooz, J., Anderson, C.L., Karreman, C., Meyer zu, H.D., Schmidt, G., Ruonala, M., Namikawa, K., Harms, G.S., Carpy, A., Macek, B., Koster, R.W., and Rajalingam, K. (2012). IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 31, 14-28.
56. Olayioye, M.A., Kaufmann, H., Pakusch, M., Vaux, D.L., Lindeman, G.J., and Visvader, J.E. (2005). XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. Cell Death.Differ. 12, 87-90.
57. Petersen, S.L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., Harran, P., and Wang, X. (2007). Autocrine TNFalpha signaling renders human cancer cells susceptible to Smacmimetic- induced apoptosis. Cancer Cell. 12, 445-456.
58. Ramp, U., Krieg, T., Caliskan, E., Mahotka, C., Ebert, T., Willers, R., Gabbert, H.E., and Gerharz, C.D. (2004). XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum.Pathol. 35, 1022-1028.
59. Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M., and Goeddel, D.V. (1995). The TNFR2- TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 83, 1243-1252.
60. Samuel, T., Welsh, K., Lober, T., Togo, S.H., Zapata, J.M., and Reed, J.C. (2006). Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J.Biol.Chem. 281, 1080-1090.
61. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
62. Schile, A.J., Garcia-Fernandez, M., and Steller, H. (2008). Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 22, 2256-2266.
63. Schimmer, A.D., Herr, W., Hanel, M., Borthakur, G., Frankel, A., Horst, H.A., Martin, S., Kassis, J., Desjardins, P., Seiter, K., Fiedler, W., Noppeney, R., Giagounidis, A., Jacob, C., Jolivet, J., Tallman, M.S., and Koschmieder, S. (2011). Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin.Lymphoma Myeloma.Leuk. 11, 433-438.
64. Schimmer, A.D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.J., Pedersen, I.M., Kitada, S., Scott, F.L., Bailly-Maitre, B., Glinsky, G., Scudiero, D., Sausville, E., Salvesen, G., Nefzi, A., Ostresh, J.M., Houghten, R.A., and Reed, J.C. (2004). Smallmolecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 5, 25-35.
65. Seligson, D.B., Hongo, F., Huerta-Yepez, S., Mizutani, Y., Miki, T., Yu, H., Horvath, S., Chia, D., Goodglick, L., and Bonavida, B. (2007). Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin.Cancer Res. 13, 6056-6063.
66. Shi, Y.H., Ding, W.X., Zhou, J., He, J.Y., Xu, Y., Gambotto, A.A., Rabinowich, H., Fan, J., and Yin, X.M. (2008). Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 48, 497-507.
67. Srinivasula, S.M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., Lee, R.A., Robbins, P.D., Fernandes-Alnemri, T., Shi, Y., and Alnemri, E.S. (2001). A conserved XIAPinteraction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 410, 112-116.
68. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J.A., Binder, B.R., and Lipp, J. (1998). Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J.Exp.Med. 188, 211- 216.
69. Sun, H., Nikolovska-Coleska, Z., Yang, C.Y., Xu, L., Tomita, Y., Krajewski, K., Roller, P.P., and Wang, S. (2004). Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J.Med.Chem. 47, 4147-4150.
70. Sun, H., Stuckey, J.A., Nikolovska-Coleska, Z., Qin, D., Meagher, J.L., Qiu, S., Lu, J., Yang, C.Y., Saito, N.G., and Wang, S. (2008). Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J.Med.Chem. 51, 7169-7180.
71. Sung, K.W., Choi, J., Hwang, Y.K., Lee, S.J., Kim, H.J., Kim, J.Y., Cho, E.J., Yoo, K.H., and Koo, H.H. (2009). Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J.Korean Med.Sci. 24, 605-613.
72. Suzuki, Y., Nakabayashi, Y., and Takahashi, R. (2001). Ubiquitin-protein ligase activity of Xlinked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc.Natl.Acad.Sci.U.S.A. 98, 8662-8667.
73. Tamm, I., Kornblau, S.M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D.A., Tudor, G., Qui, Y.H., Monks, A., Andreeff, M., and Reed, J.C. (2000). Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin.Cancer Res. 6, 1796-1803.
74. Tamm, I., Richter, S., Oltersdorf, D., Creutzig, U., Harbott, J., Scholz, F., Karawajew, L., Ludwig, W.D., and Wuchter, C. (2004a). High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin.Cancer Res. 10, 3737-3744.
75. Tamm, I., Richter, S., Scholz, F., Schmelz, K., Oltersdorf, D., Karawajew, L., Schoch, C., Haferlach, T., Ludwig, W.D., and Wuchter, C. (2004b). XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol.J. 5, 489-495.
76. Varfolomeev, E., Alicke, B., Elliott, J.M., Zobel, K., West, K., Wong, H., Scheer, J.M., Ashkenazi, A., Gould, S.E., Fairbrother, W.J., and Vucic, D. (2009). X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J.Biol.Chem. 284, 34553-34560.
77. Varfolomeev, E., Blankenship, J.W., Wayson, S.M., Fedorova, A.V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J.N., Elliott, L.O., Wallweber, H.J., Flygare, J.A., Fairbrother, W.J., Deshayes, K., Dixit, V.M., and Vucic, D. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 131, 669-681.
78. Varfolomeev, E., Goncharov, T., Fedorova, A.V., Dynek, J.N., Zobel, K., Deshayes, K., Fairbrother, W.J., and Vucic, D. (2008). c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J.Biol.Chem. 283, 24295- 24299.
79. Varfolomeev, E., Wayson, S.M., Dixit, V.M., Fairbrother, W.J., and Vucic, D. (2006). The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J.Biol.Chem. 281, 29022-29029.
80. Vince, J.E., Wong, W.W., Khan, N., Feltham, R., Chau, D., Ahmed, A.U., Benetatos, C.A., Chunduru, S.K., Condon, S.M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B.A., Koentgen, F., Vaux, D.L., and Silke, J. (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 131, 682-693.
81. Wist, A.D., Gu, L., Riedl, S.J., Shi, Y., and McLendon, G.L. (2007). Structure-activity based study of the Smac-binding pocket within the BIR3 domain of XIAP. Bioorg.Med.Chem. 15, 2935-2943.
82. Xie, P. (2013). TRAF molecules in cell signaling and in human diseases. J.Mol.Signal. 8, 7-8.
83. Xu, Y.C., Liu, Q., Dai, J.Q., Yin, Z.Q., Tang, L., Ma, Y., Lin, X.L., and Wang, H.X. (2014). Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients. Med.Oncol. 31, 764-0764.
84. Yan, Y., Mahotka, C., Heikaus, S., Shibata, T., Wethkamp, N., Liebmann, J., Suschek, C.V., Guo, Y., Gabbert, H.E., Gerharz, C.D., and Ramp, U. (2004). Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br.J.Cancer. 91, 1349-1357.
85. Zhang, S., Ding, F., Luo, A., Chen, A., Yu, Z., Ren, S., Liu, Z., and Zhang, L. (2007). XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol.Ther. 6, 973-980.
86. Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G., and Wu, H. (2010). Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol.Cell. 38, 101-113.
87. Zong, W.X., Edelstein, L.C., Chen, C., Bash, J., and Gelinas, C. (1999). The prosurvival Bcl- 2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalphainduced apoptosis. Genes Dev. 13, 382-387.